Prevalence of xylazine among people who inject drugs seeking medical care at a syringe services program clinic : Miami, Florida, 2023
© 2023 The Authors. Published by Elsevier B.V..
Background: We aimed to report the preliminary xylazine prevalence among people who inject drugs (PWID) treated at a student-run free clinic in Miami, FL, USA and to identify characteristics associated with screening positive for xylazine.
Methods: A retrospective chart review of 59 patients presenting to a syringe services program (SSP) clinic in was conducted between April 27th and August 17th, 2023. We measured presence of xylazine with rapid visual immunoassay strips on patient urine samples.
Results: Xylazine was present in 55.9 % (33/59) of urine samples including 2 without detected opioids. Xylazine presence was significantly associated with unsheltered homelessness (p = 0.018), presence of wound(s) (p = 0.008), and testing positive for hepatitis C antibody (p = 0.014), fentanyl (p = 0.005) and MDMA (p = 0.002).
Conclusions: A high prevalence of xylazine in the Southeastern United States furthers evidence of the geographical spread of xylazine and rapidly evolving illicit drug supply. Widespread xylazine screening is urgently needed to inform people who inject drugs and to studyinterventions to minimize harms associated with xylazine.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
---|---|
Enthalten in: |
Drug and alcohol dependence reports - 9(2023) vom: 05. Dez., Seite 100209 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Hauschild, Maia H [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 07.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1016/j.dadr.2023.100209 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM366531484 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM366531484 | ||
003 | DE-627 | ||
005 | 20240207232212.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240108s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.dadr.2023.100209 |2 doi | |
028 | 5 | 2 | |a pubmed24n1283.xml |
035 | |a (DE-627)NLM366531484 | ||
035 | |a (NLM)38162510 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Hauschild, Maia H |e verfasserin |4 aut | |
245 | 1 | 0 | |a Prevalence of xylazine among people who inject drugs seeking medical care at a syringe services program clinic |b Miami, Florida, 2023 |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 07.02.2024 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a © 2023 The Authors. Published by Elsevier B.V. | ||
520 | |a Background: We aimed to report the preliminary xylazine prevalence among people who inject drugs (PWID) treated at a student-run free clinic in Miami, FL, USA and to identify characteristics associated with screening positive for xylazine | ||
520 | |a Methods: A retrospective chart review of 59 patients presenting to a syringe services program (SSP) clinic in was conducted between April 27th and August 17th, 2023. We measured presence of xylazine with rapid visual immunoassay strips on patient urine samples | ||
520 | |a Results: Xylazine was present in 55.9 % (33/59) of urine samples including 2 without detected opioids. Xylazine presence was significantly associated with unsheltered homelessness (p = 0.018), presence of wound(s) (p = 0.008), and testing positive for hepatitis C antibody (p = 0.014), fentanyl (p = 0.005) and MDMA (p = 0.002) | ||
520 | |a Conclusions: A high prevalence of xylazine in the Southeastern United States furthers evidence of the geographical spread of xylazine and rapidly evolving illicit drug supply. Widespread xylazine screening is urgently needed to inform people who inject drugs and to studyinterventions to minimize harms associated with xylazine | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Syringe services programs | |
650 | 4 | |a Wounds | |
650 | 4 | |a Xylazine | |
700 | 1 | |a Warp, Peyton V |e verfasserin |4 aut | |
700 | 1 | |a Tookes, Hansel E |e verfasserin |4 aut | |
700 | 1 | |a Yakir, Ella |e verfasserin |4 aut | |
700 | 1 | |a Malhotra, Bharat |e verfasserin |4 aut | |
700 | 1 | |a Malik, Subul |e verfasserin |4 aut | |
700 | 1 | |a Owens, Cyrus |e verfasserin |4 aut | |
700 | 1 | |a Suarez, Edward |c Jr |e verfasserin |4 aut | |
700 | 1 | |a Serota, David P |e verfasserin |4 aut | |
700 | 1 | |a Bartholomew, Tyler S |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Drug and alcohol dependence reports |d 2021 |g 9(2023) vom: 05. Dez., Seite 100209 |w (DE-627)NLM336882270 |x 2772-7246 |7 nnns |
773 | 1 | 8 | |g volume:9 |g year:2023 |g day:05 |g month:12 |g pages:100209 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.dadr.2023.100209 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 9 |j 2023 |b 05 |c 12 |h 100209 |